About: Part II. High-dose methotrexate with leucovorin rescue for severe COVID-19: An immune stabilization strategy for SARS-CoV-2 induced ‘PANIC’ attack()

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Part II. High-dose methotrexate with leucovorin rescue for severe COVID-19: An immune stabilization strategy for SARS-CoV-2 induced ‘PANIC’ attack() Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Part II. High-dose methotrexate with leucovorin rescue for severe COVID-19: An immune stabilization strategy for SARS-CoV-2 induced ‘PANIC’ attack()
Creator	Steinman, Lawrence Frohman, Teresa Frohman, Elliot Cruz, Cruz, Roberto Longmuir, Reid Parsons, Matthew Villemarette-Pittman, Nicole Zamvil, Scott Cruzsaldana@austin, Roberto Edu, ; Edu, Matthew Edu;, Matthew Edu;, Nville@lsuhsc Edu;, Reid Edu;, Steinman@stanford Frohman@austin, Elliot Frohman@austin, Teresa Longmuir, Parsons, Roberto, Alejandro
Source	Elsevier; Medline; PMC; WHO
abstract	Here, in Part II of a duology on the characterization and potential treatment for COVID-19, we characterize the application of an innovative treatment regimen for the prevention of the transition from mild to severe COVID-19, as well as detail an intensive immunotherapy intervention hypothesis. We propose as a putative randomized controlled trial that high-dose methotrexate with leucovorin (HDMTX-LR) rescue can abolish ‘PANIC’, thereby ‘left-shifting’ severe COVID-19 patients to the group majority of those infected with the SARS-CoV-2 virus, who are designated as having mild, even asymptomatic, disease. HDMTX-LR is endowed with broadly pleiotropic properties and is a repurposed, generic, inexpensive, and widely available agent which can be administered early in the course of severe COVID-19 thus rescuing the critical and irreplaceable gas-exchange alveoli. Further, we describe a preventative treatment intervention regimen for those designated as having mild to moderate COVID-19 disease, but who exhibit features which herald the transition to the severe variant of this novel Coronavirus. Both of our proposed hypothesis-driven questions should be urgently subjected to rigorous assessment in the context of randomized controlled trials, in order to confirm or refute the contention that the approaches characterized herein, are in fact capable of exerting mitigating, if not abolishing, effects upon the SARS-CoV-2 triggering of the ‘PANIC Attack’. Confirmation of our immunotherapy hypothesis would have far-reaching ramifications for the current pandemic, along with yielding invaluable lessons from which we can more effectively prepare for the next challenge to global health.
has issue date	2020-05-21(xsd:dateTime)
bibo:doi	10.1016/j.jns.2020.116935
bibo:pmid	32534807
has license	no-cc
sha1sum (hex)	25ba212f9723594b8351c198b7080f9e3e71f075
schema:url	https://doi.org/10.1016/j.jns.2020.116935
resource representing a document's title	Part II. High-dose methotrexate with leucovorin rescue for severe COVID-19: An immune stabilization strategy for SARS-CoV-2 induced ‘PANIC’ attack()
has PubMed Central identifier	PMC7241359
has PubMed identifier	32534807
schema:publication	J Neurol Sci
resource representing a document's body	covid:25ba212f9723594b8351c198b7080f9e3e71f075#body_text
is schema:about of	named entity 'COVID-19' named entity 'content' named entity 'Rescue' named entity 'Lawrence' named entity 'manuscript' named entity 'content' named entity 'Teresa' named entity 'INDUCED' named entity 'RESCUE' named entity 'SARS-COV-2' named entity 'immune' named entity 'cite' named entity 'Frohman' named entity 'SARS-CoV-2' named entity 'revision' named entity 'induced' named entity 'COVID-19' named entity 'methotrexate' named entity 'bioenergetic' named entity 'spike protein' named entity 'immunotherapy' named entity 'IL-6' named entity 'lung' named entity 'cross-species' named entity 'protein' named entity 'transmembrane' named entity 'cytokines' named entity 'chronic cough' named entity 'metabolic' named entity 'chromosomal' named entity 'HMGB1' named entity 'thoracic cage' named entity 'syncytia' named entity 'steroids' named entity 'cough' named entity 'inflammatory cells' named entity 'PANIC Attack' named entity 'dextromethorphan' named entity 'proinflammatory' named entity 'SARS-CoV-2' named entity 'immune effector cells' named entity 'immune cells' named entity 'TH1' named entity 'liver toxicity' named entity 'microbe' named entity 'monocytes' named entity 'SARS' named entity 'oxygen' named entity 'unintended consequences' named entity 'complement fixation' named entity 'SARS-CoV' named entity 'intracellular' named entity 'morbidity' named entity 'remission' named entity 'TGFβ' named entity 'oxygen' named entity 'CCL2' named entity 'pulse oximetry' named entity 'hydroxychloroquine' named entity 'Pulmonary toilet' named entity 'lungs'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software